Cargando…

Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021

Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Drzymalla, Emily, Moonesinghe, Ramal, Kolor, Katherine, Khoury, Muin J., Schieber, Lyna, Gundlapalli, Adi V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219022/
https://www.ncbi.nlm.nih.gov/pubmed/37240621
http://dx.doi.org/10.3390/jcm12103516
_version_ 1785048911383101440
author Drzymalla, Emily
Moonesinghe, Ramal
Kolor, Katherine
Khoury, Muin J.
Schieber, Lyna
Gundlapalli, Adi V.
author_facet Drzymalla, Emily
Moonesinghe, Ramal
Kolor, Katherine
Khoury, Muin J.
Schieber, Lyna
Gundlapalli, Adi V.
author_sort Drzymalla, Emily
collection PubMed
description Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyze COVID-19 outcomes among 853 adult PI and 1,197,430 non-PI patients who visited the emergency department. Hospitalization, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and death had higher odds in PI patients than in non-PI patients (hospitalization aOR: 2.36, 95% CI: 1.87–2.98; ICU admission aOR: 1.53, 95% CI: 1.19–1.96; IMV aOR: 1.41, 95% CI: 1.15–1.72; death aOR: 1.37, 95% CI: 1.08–1.74), and PI patients spent on average 1.91 more days in the hospital than non-PI patients when adjusted for age, sex, race/ethnicity, and chronic conditions associated with severe COVID-19. Of the largest four PI groups, selective deficiency of the immunoglobulin G subclass had the highest hospitalization frequency (75.2%). This large study of United States PI patients provides real-world evidence that PI is a risk factor for adverse COVID-19 outcomes.
format Online
Article
Text
id pubmed-10219022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102190222023-05-27 Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021 Drzymalla, Emily Moonesinghe, Ramal Kolor, Katherine Khoury, Muin J. Schieber, Lyna Gundlapalli, Adi V. J Clin Med Article Primary immunodeficiencies (PIs) are a group of diseases that increase susceptibility to infectious diseases. Few studies have examined the relationship between PI and COVID-19 outcomes. In this study, we used Premier Healthcare Database, which contains information on inpatient discharges, to analyze COVID-19 outcomes among 853 adult PI and 1,197,430 non-PI patients who visited the emergency department. Hospitalization, intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and death had higher odds in PI patients than in non-PI patients (hospitalization aOR: 2.36, 95% CI: 1.87–2.98; ICU admission aOR: 1.53, 95% CI: 1.19–1.96; IMV aOR: 1.41, 95% CI: 1.15–1.72; death aOR: 1.37, 95% CI: 1.08–1.74), and PI patients spent on average 1.91 more days in the hospital than non-PI patients when adjusted for age, sex, race/ethnicity, and chronic conditions associated with severe COVID-19. Of the largest four PI groups, selective deficiency of the immunoglobulin G subclass had the highest hospitalization frequency (75.2%). This large study of United States PI patients provides real-world evidence that PI is a risk factor for adverse COVID-19 outcomes. MDPI 2023-05-17 /pmc/articles/PMC10219022/ /pubmed/37240621 http://dx.doi.org/10.3390/jcm12103516 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Drzymalla, Emily
Moonesinghe, Ramal
Kolor, Katherine
Khoury, Muin J.
Schieber, Lyna
Gundlapalli, Adi V.
Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title_full Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title_fullStr Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title_full_unstemmed Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title_short Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020–August 2021
title_sort severity outcomes among adult patients with primary immunodeficiency and covid-19 seen in emergency departments, united states, april 2020–august 2021
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219022/
https://www.ncbi.nlm.nih.gov/pubmed/37240621
http://dx.doi.org/10.3390/jcm12103516
work_keys_str_mv AT drzymallaemily severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021
AT moonesingheramal severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021
AT kolorkatherine severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021
AT khourymuinj severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021
AT schieberlyna severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021
AT gundlapalliadiv severityoutcomesamongadultpatientswithprimaryimmunodeficiencyandcovid19seeninemergencydepartmentsunitedstatesapril2020august2021